Mitigating the Cost Burden of PAH: Evaluating the Value of Timely Treatment with Effective Therapy

Mitigating the Cost Burden of PAH: Evaluating the Value of Timely Treatment with Effective Therapy

On-Demand Webcast
FACULTY

Jeffrey D. Dunn, PharmD, MBA
Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management
Salt Lake City, Utah

Paul R. Forfia, MD
Professor of Medicine
Director, Pulmonary Hypertension, Right Heart Failure and CTEPH Program
Temple University Hospital
Philadelphia, Pennsylvania

PROVIDER STATEMENT

 Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

INTENDED LEARNERS

This activity is designed for Pharmacy directors, medical directors, and other decision makers working in managed care organizations such as private payers, pharmacy benefit managers, Medicare/Medicaid, VA/DOD, large employers, hospitals, ACOs, long-term care, and other segments. 

Learning Objectives

After participating in this activity, participants should be better able to:

  • Quantify the clinical and economic burdens associated with the delayed diagnosis, suboptimal treatment, and consequent hospitalization of patients with PAH 
  • Evaluate clinical data regarding the PAH-specific therapies as well as their mechanism of action, efficacy, safety, and implications on mitigating healthcare utilization and costs
  • Develop diagnostic, treatment, and follow-up protocols for PAH that reflect guideline recommendations and current clinical evidence and support individualized PAH care
  • Inform formulary placement and benefit design decisions with the latest cost data, treatment guidelines, and optimal PAH management strategies
CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity, a post-test assessment, and the evaluation by March 18, 2020. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: March 19, 2019
Expiration Date: March 19, 2020
Estimated Time to Complete: 1 hour

There is no fee associated with this activity.

COMMERCIAL SUPPORT

NACCME would like to thank the following companies who have supported the Mitigating the Cost Burden of PAH: Evaluating the Value of Timely Treatment with Effective Therapy; through educational grants and/or in-kind support: Actelion Pharmaceuticals US, Inc.

CONTINUING EDUCATION

 In support of improving patient care, this activity has been planned and implemented by the University of Arkansas for Medical Sciences and NACCME. University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Designation Statement

The University of Arkansas for Medical Sciences designates this on demand activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Designation Statement

These knowledge based activities will provide pharmacists up to 1.0 contact hours or 0.1 CEU. CE credit information, based on verification of on demand attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.
(JA0006201-9999-19-019-H01-P)

ANCC Designation Statement

The University of Arkansas for Medical Sciences designates this on demand activity for a maximum of 1.0 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Clinical Reviewers
Peter Oettgen MD, FACC, FAHA, FACP
Preventive Cardiology
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include, Jennifer Ilcyn, Randy Robbin, Margaret Stefan and Angelica DeMaria.

Faculty
The faculty has reported the following:

Dr. Dunn and Dr. Oettgen have disclosed no relevant financial relationships with any commercial interests.

Dr. Forfia: Consultant - Actelion, Bayer, United Therapeutics

ADA STATEMENT

North American Center for Continuing Medical Education NACCME complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.